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Although these psychosocial scales are increasingly
used, scepticism and confusion remain regarding the abil-
ity of many scales to summarise composite indices and if
they are meaningful in orienting a conclusive clinical deci-
sion. We explore some of the limitations regarding scales
use and misuse in science.
The purpose of the review by Binks et al. [1] is to eval-
uate the evidence for the efficacy of psychological inter-
vention for people with BPD. This review is extremely
important from a policy standpoint given the prevalence of
the problem (2%), the association with deliberate self-
harm and suicide, and the long-term cost to the healthcare
system due to chronicity and intense health service
demands by people with BPD.
The Authors expected that outcomes would not have
been consistently reported across the included trials and
that different measures of disease and scales had been
used (e.g., quality of life, mental state, behaviour, etc.). In
order not to miss useful observations, the Authors includ-
ed data from any rating scale as long as these instruments
had been described in a peer-reviewed journal. This broad
approach resulted in 15 outcome categories, each of which
has several measures, totalling 82 outcomes. There are six
primary outcomes, placed in five different categories. For
example, the category mental state is articulated in: (1)
general mental state; (2) not clinically important change
in general mental state (a primary outcome); (3) not any
change in general mental state; and … etc. Death is the
only outcome with no subcategories.
The advantage of the choice made by the Authors is
that the whole body of research on this topic is covered,
but at what price? The disadvantage is that a general read-
er will not go through this review as he will find himself
lost trying to understand the essence of the trial results.
Even a psychologist using a methodological approach will
be puzzled by the question: Which is an effective treatment
for borderline personality disorders? This is not easy to
answer given the multitude and fragmentation of the
instruments and outcomes presented in the review.
Multiple comparisons
After an extensive search the Authors selected seven rel-
evant randomised control trials, each enrolling between
23 and 64 patients, for a total of 262 people with an aver-
age of 37 people per study. The small size of trials relates
to a general lack of statistical power of the studies. This
means that it is difficult to show differences between the
intervention and the control groups. To avoid the risk of
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The methodologist’s point of view
L. Moja, A. Liberati, G. Virgili
Measures of disease and measurement tool
The Cochrane review “Psychological therapies for people
with borderline personality disorder (BPD)” by Binks et
al. [1] highlights a peculiarity of outcome measures in
psychology, which is also found in social sciences: the
widespread use of several types of scales which aim at tar-
geting different aspects of mental health, subjective well-
being or the general burden of illness.
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insignificant findings, trialists used a large number of rat-
ing scales to measure outcomes. Furthermore the majori-
ty of the trials analysed the scale and subscales at many
different time intervals (<6 months, by 6–12 months, by
18 months), exponentially increasing the number of com-
parisons. Performing multiple comparisons easily gener-
ates type I errors, achieving statistical significance on
specific measures with small numbers [2, 3]. It is likely
that all positive findings have been reported in the BPD
literature, whilst negative results have often been omit-
ted, leading to reporting bias. The meta-analyses in this
review suffer from the type of this bias, as reported by
Binks et al.
Clinical relevance
The clinical relevance of some of the rating tools adopt-
ed in the trials is questionable. For example, to evaluate
mental state at least four scales resulting in complex
index have been used: the Beck Depression Inventory,
the Spielberger Anger Expression Scale, the Symptoms
Check List and the Beck Anxiety Inventory. Although all
scales have been previously cited in peer-review medical
journals, we do not have basic information about their
validation. These instruments combine information from
numerous questionnaire items that span from well
defined behaviour or objective functioning (‘In the last 6
months did you attempt to kill yourself?’) to subjective
health appraisal (‘Do you feel your family cannot under-
stand you?’). Furthermore, these scales variously com-
bine frequency, severity and/or duration of symptoms
with no pre-specified priorities among these attributes.
Some focus on one psychological attribute, such as
depression or anger, while others collapse the above
attributes into one estimate. We are aware that the com-
plexity of human personality can never be satisfactorily
expressed as one score on any scale. We can, however,
make meaningful estimations of some human attributes,
but we can do that only for one attribute at time (often
referred to as unidimensionality) [4]. Confounding a
number of attributes into a single generic score makes
confident predictions from that score more hazardous
and the score an inconsistent summary of the disease. On
the basis of a complex score, it is difficult to clinically
predict if an individual (or a trial arm) is worsened or
ameliorated, as the diagnosis relies more on an illogical
process and chance than on anything objective and sci-
entific. Not knowing whether different attributes are
equally correlated may increase the risk of data dredging
and distorted reporting in any attempt to demonstrate
post-hoc differences between interventions [3]. This
problem, again, is magnified by the limited size of most
included trials.
Scale validity and reliability
Questionnaires exploring medical disease, which allow
decisions to be made about a healthcare intervention, must
be designed with respect to three key issues: reliability,
validity and referring population [5]. Reliability is the
extent to which the measurements of a test remain consis-
tent over repeated testing of the same subject under identi-
cal conditions. A scale is reliable if it yields consistent
results of the same measure. It is unreliable if repeated
measurements yield different results. A high level of relia-
bility is particularly important when the effect of an inter-
vention on psychological distress is measured using a pre-
test/post-test design. In this type of research, design and
pre-test and post-test reliability are fundamental to the
credibility of results and the ability to attribute differences
in pre-test and post-test performance to the intervention
being tested. The ability to attribute such changes is also
affected by research design.
In psychology the validity of a research instrument is
the degree to which the instrument measures what it is sup-
posed to measure. Validity is closely related to reliability
because for an instrument to be valid, it must be reliable.
It is also important to remember that instruments may in
fact be reliable even when they are not valid.
Finally it is important to know in which population the
questionnaire has been validated. Most scales may vary
with personality dimensions [5]. Prevalence of neuroti-
cism or extraversion, for example, may lead to different
response predispositions in various diagnostic groups.
Indeed it is important that a scale has been validated in the
diagnostic group in which you are interested.
In systematic reviews a decision about which scale to
include in the final analyses may be procrastinated after
the data have been collected, with a preference for stan-
dardised and validated scales.
How can we deal with complexity?
We agree with Binks et al. [1], who suggest the use of
other clinically relevant outcomes such as hospital admis-
sions, medication use or days off work in trials. These out-
comes are generally more interpretable and are strongly
related to patients’ quality of life. We need more studies
considering these meaningful outcomes and less inconsis-
tent scales. A large treatment effect will be detected
regardless of the instrument used to compare the quality of
life. The problems arise when generic instruments are used
in a broad range of patients with different diseases: these
will be less responsive in the detection of treatment-
induced changes.
Another option is to use a statistical approach such as
the bivariate meta-analysis and its extensions. This tech-
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nique simultaneously combines information on multiple
outcome measures [6]. We can model each trial arm sepa-
rately, fitting a model that assumes the study data to be
bivariate normally distributed to investigate the relation-
ship between true and surrogate outcomes. When the cor-
relations among outcome variables are known and the
included studies report true and surrogate outcomes, this
can lead to increase in efficiency of estimation.
The Campbell Collaboration, the equivalent of the
Cochrane Collaboration in the social science and education
field, suggests that meta-analysts ‘should not ignore the
dependence among study outcomes’; however, they also
note that ‘the consequences of accounting for (modelling)
dependence or ignoring it are not well understood’ [7].
The predetermined choice of a few, relevant, patient-
centred outcome measures remains the optimal way to try
to deal with complexity.
Clinician’s point of view
G.F. Gensini, R. Gusinu, A.A. Conti
Dealing with biological and clinical complexity is a daily
challenge for health operators. In order to effectively tack-
le this problem, rating tools are increasingly elaborated
and adopted in the field of healthcare. However, building a
robust and reliable scale ensuring methodological correct-
ness and clinical relevance is one of the most difficult
undertakings for healthcare professionals.
In their interesting Cochrane review, Binks et al. [1]
have considered and analysed the structured adoption of
different scales aimed at highlighting various features not
only of mental health, but also of subjective wellbeing,
and, more generally, of the overall burden of disease. Their
work deserves credit in many respects, also evidencing
how several rating tools available today in the area of the
evaluation of borderline personalities have a clinical rele-
vance that is “improvable”.
Ideally, assessment scales should be basically validat-
ed, should have acceptable sensitivity to changes in the
severity of symptoms, appropriate inter-rater and
test–retest reliability, and high internal consistency [4].
These methodological aspects are also decisive in defining
the clinical applicability of the rating tools examined.
Unfortunately, as correctly underlined by Moja et al.
in this article, even data on the real validation of the dis-
cussed rating scales are not available and consequently
analysable. In the light of this basic drawback, and also
considering that, to effectively propose reliable estima-
tions of human dimensions, probably only one dimension
at a time should be considered, from a clinician’s point of
view the careful pre-definition and identification of a lim-
ited number of really important clinical end points should
be seen as an appropriate way of trying to tackle com-
plexity in a meaningful manner. Clinicians, even those
who are not directly involved in the mental health area,
should be encouraged to actively participate in large reg-
istries to test different scales, so as to optimally combine
the identifiable elements most useful in detecting patients
at higher risk.
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